Nxera Pharma Enters into a Global License Agreement with AbbVie for NXE0033744 to Treat Inflammatory Bowel Disease

Shots: Nxera Pharma‘s subsidiary has entered into an exclusive global license agreement with AbbVie for its EP4 agonist program, incl. NXE0033744, granting AbbVie worldwide rights to develop & commercialize it for IBD Nxera will receive $100M upfront and is eligible for up to $1.37B in development & commercial milestones, plus tiered royalties on net sales; the deal is subject to customary antitrust clearances incl. HSR NXE0033744 is an investigational, oral, gut-selective EP4 receptor agonist discovered via Nxera’s NxWave platform; a completed P-I program supported its gut-restricted profile & target engagement Ref: GlobeNewswire  |   Image: Nxera Pharma & AbbVie  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Nxera Pharma Enters into a Global License Agreement with AbbVie for NXE0033744 to Treat Inflammatory Bowel Disease appeared first on PharmaShots.